
13 April 2021
Start-up GreenBone closes a EUR10m Series B round
31 March 2021
OncoResponse Raises $40.6 Million Series C Financing
24 March 2021
3B FUTURE HEALTH GP S.A.R.L. ANNOUNCES THE LAUNCH OF 3B FUTURE HEALTH FUND II
18 March 2021
Gain Therapeutics Announces Pricing of Initial Public Offering of Common Stock
9 March 2021
NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline
24 February 2021
NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board
4 February 2021
Gain Therapeutics Announces Three Late-Breaker Presentations at the 17th Annual WORLDSymposium
21 September 2020
Novellus Closes $57M Series C Financing
10 September 2020
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program
21 July 2020
Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing
14 July 2020
3B Future Health Fund Announces New Investment in iOnctura
8 June 2020
QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test
31 January 2020
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
30 January 2020
The GreenBone bone substitute achieves CE certification
15 July 2019
Helsinn Investment Fund Announces First Exit
19 March 2019
Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced
19 February 2019
Helsinn Investment Fund Invests €1 Million in Gain Therapeutics
23 January 2019
QuantuMDx & St George’s begin field study: cervical cancer screening test
30 April 2018
NovellusDx Announces It Has Completed an Equity Financing of $6 Million
28 March 2018
Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced
14 March 2018
On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn
30 January 2018
Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement
5 September 2017
AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round
16 June 2017
Helsinn Investment Fund Leads the Financial Round in GreenBone
8 May 2017
Helsinn Investment Fund Invests in Aadi Bioscience
10 October 2016
Helsinn Group Introduces Helsinn Investment Fund
10 October 2016
Helsinn Investment Fund Invests £2.0 Million in QuantuMDx
10 October 2016
Helsinn Investment Fund to Invest $3.5 Million in OncoResponse
8 August 2016
Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialisation of Pracinostat for the Treatment of Acute Myeloid Leukaemia and Other Haematologic DiseasesGet in Touch
For further information, please contact us using the form below.
Someone from the team will be in contact in due course.
Thank you for your form submission, we will get in contact with you shortly.